Title: Fecal Occult Blood Test Number: TCFHT-MD01 Activation Date: 01-January-2014 Review Date: 08-October-2017 Next Review Date: 08-October-2018

Similar documents
Title: Fecal Occult Blood Test Number: TCFHT-MD01 Activation Date: Reviewed: Next Review:

Sherry Kennedy, Executive Director 790 Bay Street, Suite 306, Toronto , x307

Title: Influenza Immunization Number: TCFHT-MD03 Activation Date: Review Date:

Therapy Activation Date: Review Date:

TEST LIST SAMPLE REQUIREMENT. 1 ml serum None

Prostate-Specific Antigen (PSA) Test

QUALITY HEALTHCARE MEN'S PHYSICAL CHECK-UP ELIGIBLE TO EARN ASIA MILES

MINISTRY OF HEALTH AND LONG-TERM CARE Primary Health Care Team FACT SHEET. New and Enhanced Incentives for Colorectal Cancer Screening

Health Screening for Nanyang Technological University (NTU)

Annual Notice to Providers (2014)

(PE-HS1, HS2, HS3, PE133A & PE134A)

CLIENT NOTICE UPDATE - August 24, *** NEW COLLECTION CONTAINTER for PARASITE BY PCR ***

Management of Needlestick and Mucous Membrane Exposures To Blood/Body Fluids

Fullerton Healthcare Screening Centres

GSK , 2.0, 18, 2014, DAIDS

2015 Annual Notice to Providers

Unfortunately you re not. So talk to your health care provider about screening today.

(HANG1, HANG2, HANG3, HANG4, HANG5)

To be used for the ease of test requisitioning on select patients only; all components may be ordered separately

CERTIFICATE OF ACCREDITATION

CERTIFICATE OF ACCREDITATION

HEALTH SCREEN CARE. VIGNE Healthcare provides a comprehensive Health Screening Package of EXCLUSIVE HEALTH SCREENING EXPERIENCE

M Series. Health Screening Just Got A Whole Lot Easier EARLY DETECTION BETTER MANAGEMENT IMPROVED OUTCOMES

A: PARTICIPANT INFORMATION

Honouring the First Nations Path of Well-being

Adams Memorial Hospital Decatur, Indiana EXPLANATION OF LABORATORY TESTS

Alaska Native Medical Center Anchorage, AK

AIDS and insurance. Information about the necessity of AIDS testing Implications of undergoing an AIDS test The choices available to you INSURANCE

REGISTRATION IS OPEN FOR SPRING SEASON 2017 SPRING SPECIAL OLYMPICS REGISTRATION BOCCE TEAM STARTS 4/4 TRACK STARTS 4/6

Specimen Collection Requirements

Specimen Collection Requirements

25-Hydroxy Vitamin D Test

Hop on The Right Track

Online catalog

NICE Guidance. Suspected Cancer in Adults COLORECTAL (2WW)

Preventive Health Guidelines

Transition to Fecal Immunochemical Testing (FIT)

CERTIFICATE OF ACCREDITATION

Your Guide to Medicare s Preventive Services

Community health day. General Robert H. Reed Recreation Center 800 Gabreski Lane, Myrtle Beach Friday, May 11 7:30-10:30 a.m.

Medicare Part B Preventive Services: Quick Reference Chart January 2009

Kaiser Permanente 2012 Sample Fee List Members in any deductible plan 1 can use this list to help estimate their charges.

SCREENING. Highlights. Introduction HEALTH STATUS REPORT CHAPTER 9: SEPTEMBER 2016

Kaiser Permanente 2015 Sample Fee List 1

th Medical Group Report Card

FULL REGISTRATION (365-DAY RULE EXEMPT) APPLICATION FOR PATHWAY 1

Screening & Surveillance Guidelines

Saskatchewan ND Price List

We look forward to seeing you. Please feel free to call us with any questions.

NHS KINGSTON. Contents

12% savings on selected Men/Women Deluxe Health & Wellbeing Physical Check Up Plans

OSCAR EMR Cancer Screening Guidelines

Men s Health Hormone Self-Assessment

CERTIFICATE OF ACCREDITATION

VERSION STUDENT. Cases in Population-Oriented Prevention (C-POP)-based teaching cases. A Critical Look at Prevention: Colorectal Cancer Screening

Kaiser Permanente 2013 Sample Fee List

Colorectal Cancer- QI process and clinic success: A Case Study at Atascosa Health Center

Prostate cancer was the most commonly diagnosed type of cancer among Peel and Ontario male seniors in 2002.

Standing Order Policy

Quality ID #439: Age Appropriate Screening Colonoscopy National Quality Strategy Domain: Efficiency and Cost Reduction

Kildeer CCSD 96. The Empower Wellness Screening Program. Thoughtfully designed to help you take control of your health

Preventive Services Explained

CLIA APPROVED PROFICIENCY TESTING PROGRAMS ACCUTEST, INC. P.O. Box 999 Westford, Massachusetts (800)

WALNUT CREEK FAMILY PRACTICE 4303 JODECO ROAD MCDONOUGH, GA

FREQUENTLY ASKED QUESTIONS

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers

Testing Activation Date: Review Date: Dr. Beverley Jackson 726 Bloor Street West, Suite 207;

Wellness Along the Cancer Journey: Healthy Habits and Cancer Screening Revised October 2015 Chapter 7: Cancer Screening and Early Detection of Cancer

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

M.D.IPA, M.D.IPA Preferred, Optimum Choice and Optimum Choice Preferred STAT Laboratory List Revised Jan. 5, 2017

ROTUNDA HOSPITAL DEPARTMENT OF LABORATORY MEDICINE

Care1st Health Plan Taking Quality to the Next Level REPORTING YEAR HEDIS Summary - MPL (Measurement Year 2012)

Get to know yourself better. Attend our health screening event.

lab Test Name notes on collection container type CBC AUTO HEMOGLOBIN & HEMATOCRIT

2017 Preventive Health Care Guidelines Free preventive care to help you be your healthiest.

COLORECTAL CANCER SCREENING COLLABORATIVE FINAL REPORT September 2012

Get to know yourself better. Attend our health screening event.

BASIC METABOLIC PANEL

CERTIFICATE OF ACCREDITATION

WSLH. Calibration Verification/ Linearity Products. roficiency. esting. Products provided in partnership with:

Preventive Health Coverage

SCHEDULE OF BENEFITS PLAN M7

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program

ColonCancerCheck Program Report

Chronic Benefit Application Form Cardiovascular Disease and Diabetes

Table of Contents. Early Identification Chart Biometric Screening Comprehensive Cardiovascular Disease Risk Assessment...

PATIENT REGISTRATION FORM. Last Name: First Name: Initial: Address: City: State: Zip Code: Date of Birth: / / Social: - - address:

ASPEN MOUNTAIN MEDICAL CENTER. Lab Health Fair

Prevents future health problems. You receive these services without having any specific symptoms.

1101 First Colonial Road, Suite 300, Virginia Beach, VA Phone (757) Fax (757)

Rapid Laboratories In House Tests

ISO 15189:2012 Internationally-Recognized Accredited Laboratory. SPECTRA EAST, INC. Rockleigh, NJ

CLINICAL PRACTICE GUIDELINE FOR COLORECTAL CANCER SCREENING

Count y of Dupage. The Empower Wellness Screening Program. Thoughtfully designed to help you take control of your health

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Preventive Health Guidelines for Providers

Transcription:

MEDICAL DIRECTIVE Title: Fecal Occult Blood Test Number: TCFHT-MD01 Activation Date: 01-January-2014 Review Date: 08-October-2017 Next Review Date: 08-October-2018 Sponsoring/Contact Person(s) (name, position, contact particulars): Dr. Mira Barman 790 Bay St. Suite 302 Toronto, ON M5G 1N8 416-585-9555 Vicki McGregor, RN 790 Bay St. Suite 302 Toronto, ON M5G 1N8 416-585-9555 Sherry Kennedy, Executive Director skennedy@tcfht.on.ca 790 Bay Street, Suite 306 Toronto, Ontario M5G 1N8 416-260-1315, x307 Order and/or Delegated Procedure: Appendix Attached: o Yes þ No Implementers may order a Fecal Occult Blood Test (FOBT) for colorectal cancer (CRC) screening in accordance with the conditions identified in this directive. Recipient Patients: Appendix Attached: þ Yes No Title: Appendix A Authorizer Approval Form Recipients must: Be active patients of a TCFHT primary care provider who has approved this directive by signing the Authorizer Approval Form Be 50 to 74 years of age* Meet the conditions of average risk for colorectal cancer, as identified in this directive * Eligible if they are 49 years old and their 50 th birthday is within 60 days of application of the directive Authorized Implementers: Appendix Attached: þ Yes No Title: Appendix B Implementer Approval Form

2 Implementer must be a TCFHT employed Regulated Health Care Provider or Physician Assistant (under the supervision of a physician). Implementers must have completed the following training and sign the Implementer Approval Form: Review the entire Health Care Professionals section of the Ontario Ministry of Health and Long Term Care ColonCancerCheck program website, accessible from: http://health.gov.on.ca/en/pro/programs/coloncancercheck/ Review the following Cancer Care Ontario articles: a. Cancer Care Ontario. (2016). Screening Guidelines Colon Cancer, accessible from: https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/ b. Cancer Care Ontario. (2016). About ColonCancerCheck, accessible from: https://www.cancercare.on.ca/pcs/screening/coloscreening/cccworks/ Review the following articles, accessible from http://www.uptodate.com: a. Doubeni, C. (2017). Screening for colorectal cancer: Strategies in patients at average risk. b. Doubeni, C. (2017). Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy. Indications: Appendix Attached: þ Yes No Title: Appendix C CRC (FOBT) Screening Requisition Implementers may order a ColonCancerCheck FOBT for eligible patients who are 50 to 74 years old* who are at average risk of CRC. Implementers may order the FOBT using a Ministry of Health and Long-Term Care Laboratory Requisition. Average Risk (eligible for FOBT): Patients age 50-74 with no first-degree relatives who have been diagnosed with CRC (Cancer Care Ontario, 2016). No personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2016). No personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn s disease) (Cancer Care Ontario, 2016). Increased Risk (not eligible for FOBT): Patients who have a personal history of CRC (Cancer Care Ontario, 2016). Patients who have a family history that includes one or more first-degree relatives who have been diagnosed with CRC (Cancer Care Ontario, 2016). Patients with a personal history of pre-cancerous colorectal polyps requiring surveillance (Cancer Care Ontario, 2016) Patients who have a personal history of inflammatory bowel disease (i.e., ulcerative colitis or Crohn s disease) (Cancer Care Ontario, 2016). Patients who have average risk for CRC and have a normal colonoscopy on file within the last 10 years (Doubeni, 2017). * Eligible if they are 49 years old and their 50 th birthday is within 60 days of application of the directive

3 Consent: Appendix Attached: þ Yes No Title: Appendix D Turning 50 CRC Screening (FOBT) Letter The patient has enrolled with their provider at the Taddle Creek FHT. Therefore, consent to receive health information and notification of screening eligibility is implied. A letter will accompany the FOBT kit in the mail, which will encourage the patient to contact their provider should they have questions. Once receiving the FOBT kit in the mail, the patient completes the test by his or her own volition. At the 30-60-day follow up reminder call, the implementer will discuss the FOBT kit with the patient and if they do not consent to the screening, it will be noted to their EMR for future reference. Guidelines for Implementing the Order/Procedure: Appendix Attached: Yes þ No The purpose of this medical directive is to enhance TCFHT patients access to CRC screening, which is in accordance with provincial cancer screening guidelines Cancer Care Ontario Guidelines for Breast, Cervical, & Colorectal Cancer Screening (Cancer Care Ontario, 2016). Documentation and Communication: Appendix Attached: Yes þ No Implementers will document that they have reviewed an eligible patient s EMR and ordered an FOBT using the Turning 50 CRC (FOBT) Screening Program Encounter Assistant custom form. The implementer will send a message in Practice Solutions to the patient s primary care provider, indicating that they have ordered an FOBT for the patient. The implementer will send a delayed message to themselves in 60 days to follow up with the patient via phone if the FOBT test is not completed within this timeframe. After this 60 day follow up phone call, no further follow up is required. Review and Quality Monitoring Guidelines: Appendix Attached: Yes þ No Routine review will occur annually on the anniversary of the activation date. Review will involve a collaboration between the authorizing primary care providers and the approved implementers. If new information becomes available between routine reviews, such as the publishing of new clinical practice guidelines, and particularily if this new information has implications for unexpected outcomes, the directive will be reviewed by an authorizing primary care provider and a mimimum of one implementer At any such time that issues related to the use of this directive are identified, TCFHT must act upon the concerns and immediately undertake a review of the directive by the authorizing primary care providers and the authorized implementers. This medical directive can be placed on hold if routine review processes are not completed, or if indicated for an ad hoc review. During the hold, implementers cannot perform the procedures under authority of the directive and must obtain direct, patient-specific orders for the procedure until it is renewed.

4 References: Cancer Care Ontario. (2016). Cancer screening guidelines for breast, cervical, & colorectal cancer screening. Retrieved from https://www.cancercare.on.ca/common/pages/userfile.aspx?fileid=273767 Cancer Care Ontario. (2016). About ColonCancerCheck. Retrieved from https://www.cancercare.on.ca/pcs/screening/coloscreening/cccworks/ Cancer Care Ontario. (2016). Screening Guidelines Colon Cancer Check. Retrieved from https://www.cancercare.on.ca/pcs/screening/coloscreening/cccstandardsguidelines/ Doubeni, C. (2017). Screening for colorectal cancer: Strategies in patients at average risk. Retrieved from http://www.uptodate.com Doubeni, C. (2017). Tests for screening for colorectal cancer: Stool tests, radiologic imaging and endoscopy. Retrieved from http://www.uptodate.com NOTE: This medical directive is based on TCFHT s previous medical directive PH-1 entitled, Preventive Health, which required revision in formatting to reflect the growth of the TCFHT organization. The majority of the content of PH-1 has remained the same for the revised TCFHT-MD01 version. Therefore, all approved Implementers and Authorizers for medical directive PH-1 Preventive Health have grandfathered approval for TCFHT-MD01 Fecal Occult Blood Test.

Appendix A: 5 Authorizer Approval Form Name Signature Date

Appendix B: 6 Implementer Approval Form To be signed when the implementer has completed the required preparation, and feel they have the knowledge, skill, and judgement to competently carry out the actions outlined in this directive. Name Signature Date Appendix C:

Preventive Health CRC Screening Requisition 7 Name Ministry of Health and Long-Term Care Laboratory Requisition Requisitioning Clinician / Practitioner Laboratory Use Only Address Additional Clinical Information (e.g. diagnosis) Clinician/Practitioner s Contact Number for Urgent Results Service Date yyyy mm dd Clinician/Practitioner Number CPSO / Registration No. Health Number Version Sex Date of Birth yyyy mm dd M F Check ( ) one: OHIP/Insured Third Party / Uninsured WSIB ( ) Province Other Provincial Registration Number Patient s Last Name (as per OHIP Card) Patient s Telephone Contact Number ( ) Patient s First & Middle Names (as per OHIP Card) Copy to: Clinician/Practitioner Last Name First Name Patient s Address (including Postal Code) Address Note: Separate requisitions are required for cytology, histology / pathology and tests performed by Public Health Laboratory X Biochemistry Glucose HbA1C TSH Creatinine (egfr) Uric Acid Sodium Potassium Chloride CK ALT Alk. Phosphatase Bilirubin Albumin Lipid Assessment (includes Cholesterol, HDL-C, Triglycerides, calculated LDL-C & Chol/HDL-C ratio; individual lipid tests may be ordered in the Other Tests section of this form) Vitamin B12 Ferritin Albumin / Creatinine Ratio, Urine Urinalysis (Chemical) Neonatal Bilirubin: Child s Age: Clinician/Practitioner s tel. no. ( ) Patient s 24 hr telephone no. Therapeutic Drug Monitoring: Name of Drug #1 Name of Drug #2 Time Collected #1 Time of Last Dose #1 Time of Next Dose #1 Random days ( ) I hereby certify the tests ordered are not for registered in or out patients of a hospital. #2 #2 #2 Fasting hours X Hematology CBC Prothrombin Time (INR) Immunology Pregnancy test (Urine) Mononucleosis Screen Rubella Prenatal: ABO, RhD, Antibody Screen (titre and ident. if positive) Repeat Prenatal Antibodies Microbiology ID & Sensitivities (if warranted) Cervical Vaginal Vaginal / Rectal Group B Strep Chlamydia (specify source): GC (specify source): Sputum Throat Wound (specify source): Urine Stool Culture Stool Ova & Parasites Other Swabs / Pus (specify source): Specimen Collection Time 24 hour clock Date Fecal Occult Blood Test (FOBT) (check one) FOBT (non CCC) Laboratory Use Only yyyy/mm/dd X Viral Hepatitis (check one only) Acute Hepatitis Chronic Hepatitis Immune Status / Previous Exposure Specify: Hepatitis A Hepatitis B Hepatitis C or order individual hepatitis tests in the Other Tests section below Prostate Specific Antigen (PSA) Total PSA Specify one below: Free PSA Insured Meets OHIP eligibility criteria Uninsured Screening: Patient responsible for payment Vitamin D (25-Hydroxy) Insured Meets OHIP eligibility criteria: osteopenia; osteoporosis; rickets; renal disease; malabsorption syndromes; medications affecting vitamin D metabolism Uninsured Patient responsible for payment Other Tests one test per line ColonCancerCheck FOBT (CCC) no other test can be ordered on this form X Clinician/Practitioner Signature Date 4422 84 (2010/09) Queen s Printer for Ontario, 2010 7530 4581

Appendix D: 8 Turning 50 CRC Screening (FOBT) Letter Implementer Name Implementer Taddle Creek FHT Contact Information Date Dear Patient s First Name, I am the Registered Nurse that works with your primary care provider. Our records show that you will soon be turning 50 years old. Happy Birthday! This is an important milestone in your life and an opportunity to focus on your health. As part of your primary care team, I m committed to helping you be as healthy as possible. A key part of maintaining your health is the prevention and screening of chronic diseases. Our records show that you are due for colorectal cancer screening: Colorectal Cancer Screening Adults aged 50 to 74 are encouraged to do the Fecal Occult Blood Test (FOBT) every 2 years. I have included an FOBT kit in this package. Please review the instructions, do the FOBT test as soon as you can, and pop the kit in the mail when you re done. FOBT has been found to decrease the risk of dying from colorectal cancer. A person with colorectal cancer has a 90% chance of being cured if the cancer is caught early with screening. Go to www.youtube.com and search Home Screening for Colon Cancer (FOBT) for more details. Note: If you have a personal or family history of colorectal cancer, FOBT screening may not be appropriate. In this case, please contact us to discuss what screening is recommended for you. If in 2 months we have not received your FOBT results, I will call you to follow up. As part of your primary care team, I appreciate the opportunity to work with you to enhance your health and prevent illness. Should you have any questions or concerns, feel free to contact me. Yours truly, Implementer Name and Signature